Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00104013|
Recruitment Status : Completed
First Posted : February 21, 2005
Last Update Posted : August 21, 2008
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Drug: xaliproden (SR57746A)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1455 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||November 2007|
|Actual Study Completion Date :||November 2007|
- Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.
- Mini-Mental State Examination, Alzheimer's Disease assessment scale-activities of daily life.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00104013
|Study Director:||ICD CSD||Sanofi|